Back to mobile site
Get it on Google Play

IMUNON restructures operations to focus on phase 3 ovarian cancer trial

February 5, 2026 8:05 AM EST Send to a Friend
IMUNON Inc. (NASDAQ: IMNN) announced a strategic reorganization that will reduce headcount and operating expenses to focus resources on its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login